Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ted. They should also talk to their doctor about alcohol consumption. Patients should tell their doctor about all their medicines, including those for migraine, to avoid a potentially life-threatening condition. Taking Duloxetine with NSAID pain relievers, aspirin, or blood thinners may increase bleeding risk. Patients should consult with their doctor before stopping Duloxetine or changing the dose and if they are pregnant or nursing.

Patients taking Duloxetine may experience dizziness or fainting upon standing. The most common side effects of Duloxetine include nausea, dry mouth, sleepiness, and constipation. This is not a complete list of side effects.

For full Patient Information, visit www.Cymbalta.com.

For full Prescribing Information, including Boxed Warning and medication guide, visit www.Cymbalta.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

P-LLY

This press release contains forward-looking statements about the potential of Duloxetine for the management of chronic pain, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the resubmission will occur as currently planned,
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
(Date:11/26/2014)... Dr. Rod J. Rohrich, ... in the Department of Plastic Surgery at UT ... fat grafting, and modern lift-and-fill facelifts before colleagues ... held by the American Society of Plastic Surgeons ... facial structure were explored in detail during Dr. ...
(Date:11/26/2014)... Alex Kramer HealthDay ... People with rheumatoid arthritis may be more likely to achieve ... new research. The study found that those who were ... Being underweight also lowered the odds of remission. "Medication ... population," said Dr. Susan Goodman, the study,s lead author and ...
(Date:11/26/2014)... Amy Norton HealthDay Reporter ... people have long believed their dogs understand what they,re saying, ... emotion of words in a human-like way. Past research ... speech -- including the actual content and the emotional tone, ... give a deeper insight into the canine brain, according to ...
(Date:11/26/2014)... Even after they,re cleared to play following a concussion, ... suggests they may not be fully recovered, a new ... may be symptom-free and cleared by MLB [Major League ... of concussion on the complex motor skills required for ... Dr. Jeffrey Bazarian, an associate professor of emergency medicine ...
(Date:11/26/2014)... (HealthDay News) -- More than half of Americans with ... memory skills, a new study suggests. As ... 1.8 million Americans over the age of 70 with ... [mental] abilities," study author Dr. Vikas Kotagal, of the ... in a journal news release. The finding is ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:Harm From Baseball Concussions May Linger, Study Finds 2Health News:Too Few Americans Undergo Dementia Screening 2
... Respondents, Lives Significantly Impacted After Breaking a BoneSpecial ... Encourage Women to Make Bone Health a Priority ... The Know My Bones Council today ... which found that one-out-of-five women with postmenopausal osteoporosis ...
... Inc., the global leader in acute ischemic stroke intervention, ... its Merci Registry, a real-world, international, post-market study of ... has enrolled patients from over 30 sites worldwide and ... largest repository of data on mechanical intervention in acute ...
... MONICA, Calif., May 14 Cord Blood America, Inc. (OTC ... company ( http://www.cordblood-america.com ) focused ... families nationwide and internationally, said today it has received a ... its own state-of-the-art laboratory for the storage of multiple stem ...
... reproductive endocrinologist Richard Sherbahn, MD, at the Advanced Fertility Center of ... more eggs retrieved -- but not a correspondingly higher rate of ... ... (PRWeb) May 14, 2009 -- Infertility specialist Richard Sherbahn, MD ...
... MEDITECH and other HIT solutions can use CPMRC,s interdisciplinary clinical content ... ... MI (Vocus) May 14, 2009 -- CPM Resource Center (CPMRC) ... provide small- and medium-sized hospitals with next-generation nursing and interdisciplinary documentation ...
... week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, ... patients suffering from moderately to severely active rheumatoid ... experienced rapid and significant improvements in signs and ... week one, and sustained at week 24 and ...
Cached Medicine News:Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 2Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 3Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 4Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 5Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 6Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 7Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 8Health News:Video: Economic Downturn Is Driving Many Osteoporotic Women to Retire Later - but Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 9Health News:Concentric Medical Announces Enrollment Milestone for Merci Registry 2Health News:Concentric Medical Announces Enrollment Milestone for Merci Registry 3Health News:Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory 2Health News:Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment 2Health News:Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment 3Health News:Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment 4Health News:CPM Resource Center and The Shams Group Partner to Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 2Health News:CPM Resource Center and The Shams Group Partner to Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 3Health News:CPM Resource Center and The Shams Group Partner to Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 4Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 2Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 3Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 4Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 5Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 6Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 7Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 8Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 9Health News:UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 10
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: